Accumetrics VerifyNow P2Y12 Check receives CE mark authorization for prognostic use Accumetrics.

Accumetrics‘ VerifyNow P2Y12 Check receives CE mark authorization for prognostic use Accumetrics, Inc.g. Clopidogrel) who are at greater risk for future cardiovascular events. Numerous research have demonstrated the link between high residual platelet reactivity and higher risk of ischemic events. Storey, MD, Professor of Cardiology at the University of Sheffield, England. The CE tag for prognostic usage of the VerifyNow P2Y12 Test in risk assessment represents a significant milestone for Accumetrics, said Timothy I. Still, President and CEO of Accumetrics. .This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an unbiased news service editorially, is an application of the Kaiser Family members Foundation, a nonpartisan healthcare policy research firm unaffiliated with Kaiser Permanente.

ADHD diagnosis on the rise among American children The amount of American children departing doctors’ offices with an attention deficit hyperactivity disorder diagnosis has risen 66 % in a decade, according to a new Northwestern Medicine study.